Revance Therapeutics, Inc.
BOTULINUM TOXIN AND THE TREATMENT OF PRIMARY DISORDERS OF MOOD AND AFFECT
Last updated:
Abstract:
The invention provides methods for treating primary disorders of mood and affect, including depressive disorders, anxiety and sleep disorders and CNS disorders comprising the administration of a neurotoxin.
Status:
Application
Type:
Utility
Filling date:
19 Apr 2021
Issue date:
7 Oct 2021